Click text to download the following document:
Biomarkers Consortium Project Use of Targeted Multiplex Proteomic Strategies to Identify Plasma-Based Biomarkers in Alzheimer’s Disease

The data described within this document represents the work of the Biomarkers Consortium Project “Use of Targeted Multiplex Proteomic Strategies to Identify Plasma-Based Biomarkers in Alzheimer’s Disease”. This project was submitted to the Biomarkers Consortium Neuroscience Steering Committee by a subgroup of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Industry Scientific Advisory Board (ISAB) for execution and was managed by a Biomarkers Consortium Project Team that includes members from academia, government and the pharmaceutical industry (for the list of Project Team members, see Appendix I); funding for this project was provided through an overage of funds raised by the Foundation for NIH for the ADNI partnership, as well as Pfizer Inc. This project is intended to be the first part of a multi-phased effort seeking to utilize samples collected by ADNI to qualify multiplex panels in both plasma and cerebrospinal fluid (CSF) to diagnose patients with Alzheimer’s Disease (AD) and monitor disease progression.